Fundz

Alentis and CSL enter a global partnership to develop lixudebart for rare kidney and liver diseases.

Oct 06, 2026

Contract Type

partnership

AllschwilManufacturing

Description

CSL and Alentis have announced a partnership to co-develop and commercialize lixudebart, with Alentis receiving an initial payment of USD 355 million and up to USD 1.2 billion in milestones. This collaboration aims to bring innovative treatments for rare kidney and liver diseases to market.

Company Information

Company

Alentis Therapeutics

Location

Allschwil, Basel-Landschaft, Switzerland

About

Alentis Therapeutics is a clinical-stage biotechnology company pioneering first-in-class antibody-drug conjugates (ADCs) and antibodies targeting Claudin-1 (CLDN1) for oncology and multi-organ fibrosis. CLDN1 is a previously unexploited target that plays a key role in the pathology of cancer and fibrotic disease. Alentis is the leading company pioneering CLDN1 ADCs and antibodies to modify and reverse the course of select diseases.

Related People

Luigi
Likely contact at this company
••••••••@••••••••

See Luigi's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Alentis Therapeutics's next move

Learn about Strategic plan

Agreement Insights

What this usually means
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies

Alentis Therapeutics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.